We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

AXIA6:BMFBOVESPAAXIA Energia SA Non-Cum Perp Pfd Registered Shs Analysis

Data as of 2026-03-14 - not real-time

R$63.03

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

AXIA Energia SA trades at BRL 63.03, just above the computed support of BRL 61.22 and below the resistance of BRL 68.82. The price sits under the 20‑day SMA (65.42) but remains above the 50‑day SMA (60.12) and far above the 200‑day SMA (46.32), indicating a mixed technical picture. Momentum is neutral with an RSI of 48, while the MACD shows a bearish divergence (histogram ‑0.70, signal “bearish”), and volume is on a decreasing trend, suggesting short‑term pressure.
Fundamentally, the stock carries a high dividend yield of 5.04 % but an unsustainable payout ratio of 140 % and a debt‑to‑equity of 66.7 %, raising concerns about cash flow durability. Earnings are expected to accelerate, reflected by a forward PE of 10.28 versus a trailing PE of 27.77**, and analysts collectively rate the stock as a “strong buy” with a median price target of **BRL 62.15**. However, the DCF‑derived fair value of **BRL 23.39** and a modest upside of **6.8 %** highlight a significant valuation gap, suggesting the market may be overpricing the shares relative to intrinsic fundamentals.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD histogram indicating potential downside
  • Decreasing volume reducing short‑term momentum
  • Price hovering just above key support level

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward earnings growth implied by low forward PE (10.28)
  • Analyst consensus strong‑buy with median target near current price
  • Attractive dividend yield if payout can be adjusted

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • High leverage (debt‑to‑equity 66.7 %) increasing financial risk
  • DCF fair value far below market price indicating overvaluation
  • Unsustainable dividend payout ratio may lead to future cuts

Key Metrics & Analysis

Financial Health

Revenue Growth-11.30%
Profit Margin15.89%
P/E Ratio27.8
ROE5.46%
ROA1.35%
Debt/Equity66.72
P/B Ratio1.5
Op. Cash FlowR$14.5B
Free Cash FlowR$7.9B
Industry P/E23.3

Technical Analysis

TrendBullish
RSI48.0
SupportR$61.22
ResistanceR$68.82
MA 20R$65.42
MA 50R$60.12
MA 200R$46.32
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair ValueR$23.39
Target PriceR$67.30
Upside/Downside6.77%
GradeOvervalued
TypeBlend
Dividend Yield5.04%

Risk Assessment

Beta0.26
Volatility37.30%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.